{"id":"placebo-by-mouth","safety":{"commonSideEffects":[{"rate":null,"effect":"Nocebo effects (adverse events attributed to placebo)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo effects are mediated by psychological expectation and conditioning, which can activate neurobiological pathways including endogenous opioid release, dopamine signaling, and immune modulation. These effects are particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue. Placebo is not inert but represents a measurable psychobiological phenomenon.","oneSentence":"Placebo produces therapeutic effects through the patient's expectation and belief that treatment is being received, activating endogenous healing mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:40.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as control in clinical trials across multiple therapeutic areas"}]},"trialDetails":[{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":"Acute Coronary Syndrome","enrollment":14194},{"nctId":"NCT06898606","phase":"PHASE1, PHASE2","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","status":"RECRUITING","sponsor":"Federal University of Latin American Integration","startDate":"2024-09-05","conditions":"Depressive Disorder","enrollment":24},{"nctId":"NCT04669158","phase":"PHASE1, PHASE2","title":"Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-07-30","conditions":"Non Alcoholic Steatohepatitis, Fibrosis","enrollment":53},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT06564818","phase":"PHASE3","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2024-12-17","conditions":"Major Depressive Disorder","enrollment":220},{"nctId":"NCT06412666","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-05-29","conditions":"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","enrollment":55},{"nctId":"NCT07008586","phase":"NA","title":"The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans.","status":"COMPLETED","sponsor":"Anglia Ruskin University","startDate":"2025-07-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT06757764","phase":"PHASE4","title":"The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-10","conditions":"Cerebral Infarction, Stenosis Artery","enrollment":2340},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14},{"nctId":"NCT06964776","phase":"PHASE1","title":"A Study of LY4268989 (MORF-057) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-01","conditions":"Healthy","enrollment":144},{"nctId":"NCT06840496","phase":"PHASE3","title":"To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome","status":"RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-09-30","conditions":"Rett Syndrome","enrollment":210},{"nctId":"NCT06274749","phase":"NA","title":"Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial","status":"RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2026-04-01","conditions":"Healthy Volunteer","enrollment":180},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT06082037","phase":"PHASE3","title":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-10-10","conditions":"Lung Transplant Rejection","enrollment":180},{"nctId":"NCT04378075","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy","status":"TERMINATED","sponsor":"PTC Therapeutics","startDate":"2020-09-28","conditions":"Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease","enrollment":68},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT04026997","phase":"PHASE2","title":"A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis","status":"TERMINATED","sponsor":"CinDome Pharma, Inc.","startDate":"2019-09-11","conditions":"Gastroparesis","enrollment":72},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT07230132","phase":"PHASE2","title":"Efficacy and Safety of ZT006 in Overweight and Obese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","startDate":"2025-12-12","conditions":"Overweight , Obesity","enrollment":184},{"nctId":"NCT07094542","phase":"PHASE2","title":"Jaw Muscle Pain Post Wisdom Molar Surgery","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-05","conditions":"Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain","enrollment":80},{"nctId":"NCT02789605","phase":"PHASE2","title":"Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-01-04","conditions":"Aphthous Stomatitis","enrollment":20},{"nctId":"NCT06006559","phase":"PHASE2","title":"A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-20","conditions":"Dengue","enrollment":108},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT02763033","phase":"PHASE2","title":"Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2017-04-26","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":107},{"nctId":"NCT03407079","phase":"PHASE2","title":"Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2018-04-05","conditions":"Healthy Volunteers, Overweight","enrollment":150},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT07144163","phase":"PHASE3","title":"A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-12-11","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT06217302","phase":"PHASE3","title":"Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Alessandro Doria","startDate":"2024-10-31","conditions":"Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1","enrollment":150},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT05677763","phase":"PHASE4","title":"OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness","status":"ACTIVE_NOT_RECRUITING","sponsor":"OM Pharma SA","startDate":"2022-12-12","conditions":"Respiratory Tract Infections, Wheezing Lower Respiratory Illness","enrollment":525},{"nctId":"NCT03835767","phase":"PHASE2","title":"Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-19","conditions":"Milk and/or Peanut Allergy","enrollment":200},{"nctId":"NCT06587945","phase":"PHASE4","title":"Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","status":"RECRUITING","sponsor":"Center for Eye Research Australia","startDate":"2025-09-19","conditions":"Retinal Detachment","enrollment":144},{"nctId":"NCT05713877","phase":"PHASE2","title":"Melatonin for Treatment of Delirium in Critically Ill Adult Patients","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2023-02-01","conditions":"Delirium","enrollment":30},{"nctId":"NCT06632600","phase":"PHASE2","title":"A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-28","conditions":"Chagas Disease","enrollment":130},{"nctId":"NCT06637631","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Crohn's Disease","enrollment":260},{"nctId":"NCT06113445","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-29","conditions":"NonSegmental Vitiligo","enrollment":467},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06113471","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-27","conditions":"NonSegmental Vitiligo","enrollment":450},{"nctId":"NCT05431088","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study in Adult and Adolescent Participants With SCD","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-09-22","conditions":"Sickle Cell Disease","enrollment":389},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT06517758","phase":"PHASE3","title":"A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-31","conditions":"Generalized Myasthenia Gravis","enrollment":146},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT07339631","phase":"PHASE1","title":"Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-01","conditions":"Low Back Pain, Paraspinal Muscle, CLBP - Chronic Low Back Pain","enrollment":40},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07181382","phase":"PHASE3","title":"Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","status":"SUSPENDED","sponsor":"GB002, Inc.","startDate":"2026-02","conditions":"Pulmonary Hypertension Associated With Interstitial Lung Disease","enrollment":480},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT06463587","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-06-25","conditions":"Generalized Myasthenia Gravis","enrollment":264},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT07218380","phase":"PHASE3","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-12","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis","enrollment":450},{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT02531516","phase":"PHASE3","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-19","conditions":"Prostatic Neoplasms","enrollment":1503},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT06810245","phase":"PHASE1","title":"Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain","status":"COMPLETED","sponsor":"Contineum Therapeutics","startDate":"2025-02-04","conditions":"Chronic Osteoarthritis Pain, Chronic Low Back Pain","enrollment":43},{"nctId":"NCT06807866","phase":"PHASE4","title":"Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-03-01","conditions":"THA","enrollment":64},{"nctId":"NCT07268638","phase":"PHASE2","title":"A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)","status":"RECRUITING","sponsor":"Akebia Therapeutics","startDate":"2025-12-03","conditions":"Focal Segmental Glomerulosclerosis","enrollment":60},{"nctId":"NCT07479550","phase":"PHASE2","title":"Anesthesia-Masked Psilocybin Therapy for Major Depression","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":"Major Depression","enrollment":10},{"nctId":"NCT02064673","phase":"PHASE3","title":"Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy","status":"RECRUITING","sponsor":"yair lotan","startDate":"2014-05","conditions":"Prostate Cancer","enrollment":608},{"nctId":"NCT06562907","phase":"PHASE1","title":"Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Weight Management","enrollment":134},{"nctId":"NCT07478328","phase":"PHASE2","title":"Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Longhua Hospital","startDate":"2026-03-08","conditions":"Ischemic Heart Disease","enrollment":60},{"nctId":"NCT06950385","phase":"PHASE3","title":"Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis","status":"RECRUITING","sponsor":"Rapamycin Holdings Inc.","startDate":"2025-07-18","conditions":"Familial Adenomatous Polyposis (FAP)","enrollment":168},{"nctId":"NCT05688956","phase":"NA","title":"Protein Supplement and Exercise Training for the Treatment of Sarcopenia Risk in Older Adults","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2023-02-01","conditions":"Sarcopenia","enrollment":46},{"nctId":"NCT07241585","phase":"NA","title":"Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-05-01","conditions":"Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":54},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07473570","phase":"PHASE1","title":"A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-01-07","conditions":"Healthy Adults","enrollment":32},{"nctId":"NCT02173756","phase":"PHASE3","title":"Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2014-06","conditions":"Cancer","enrollment":25},{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT06709014","phase":"PHASE3","title":"A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD","status":"RECRUITING","sponsor":"Annovis Bio Inc.","startDate":"2025-02-04","conditions":"Early Alzheimers Disease","enrollment":760},{"nctId":"NCT06345729","phase":"PHASE3","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-24","conditions":"Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT06404203","phase":"NA","title":"The Effect of Oral Use of Lyophilised Royal Jelly on Cognitive Functions and Immune System in Elderly Individuals","status":"COMPLETED","sponsor":"Medipol University","startDate":"2024-07-01","conditions":"Cognitive Change, Cytokine Levels, Neuroinflammation","enrollment":120},{"nctId":"NCT04335656","phase":"PHASE2","title":"Reducing Innate Inflammation in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT03519230","phase":"PHASE3","title":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2018-05-14","conditions":"Ovarian Cancer","enrollment":224},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT06901297","phase":"PHASE3","title":"The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients","status":"RECRUITING","sponsor":"Materia Medica Holding","startDate":"2025-04-03","conditions":"Rhinosinusitis, Rhinosinusitis Acute","enrollment":552},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT07058077","phase":"PHASE2, PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-21","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":153},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT06454669","phase":"PHASE2","title":"Dronabinol as an Adjunct for Reducing Pain","status":"RECRUITING","sponsor":"Christopher D. Verrico","startDate":"2024-06-15","conditions":"Low Back Pain, Chronic Pain, Back Injuries","enrollment":75},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":"Plaque Psoriasis","enrollment":752},{"nctId":"NCT06485245","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2025-04-22","conditions":"MASH","enrollment":80},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT06834997","phase":"PHASE2","title":"Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Endometriosis, Endometriosis Related Pain, Endometriosis, Pain","enrollment":""},{"nctId":"NCT06715891","phase":"PHASE3","title":"Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years","status":"RECRUITING","sponsor":"Materia Medica Holding","startDate":"2024-11-11","conditions":"Acute Respiratory Viral Infection","enrollment":374},{"nctId":"NCT04590963","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":370}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":427,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Starch tablet by mouth"],"phase":"marketed","status":"active","brandName":"Placebo by mouth","genericName":"Placebo by mouth","companyName":"Shenzhen Kangning Hospital","companyId":"shenzhen-kangning-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces therapeutic effects through the patient's expectation and belief that treatment is being received, activating endogenous healing mechanisms. Used for Used as control in clinical trials across multiple therapeutic areas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}